Combination Tx of SGLT2 Inhibitor and Exenatide May Improve Renal, Mortality Outcomes

SAN FRANCISCO – Combination treatment of a sodium-glucose cotransporter 2 (SGLT2) inhibitor with exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may protect renal function and reduce all-cause mortality risk in patients with type 2 diabetes, according to a post-hoc analysis from the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering Trial; ClinicalTrials.gov Identifier: NCT01144338) presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019.

Previous studies have shown that both SGLT2 inhibitors and GLP-1 receptor agonists may improve cardiovascular and renal outcomes. In this analysis, the researchers aimed to assess these outcomes in patients receiving a combination of exenatide and SGLT2 inhibitor, as approximately 10% of the participants in the EXSCEL study were using this combination.

The investigators propensity-matched patients receiving the combination of SGLT2 inhibitor with exenatide to 575 patients receiving exenatide but not SGLT2 inhibitor and 572

... read more at: https://www.empr.com/home/news/combination-treatment-of-sglt2-inhibitor-and-exenatide-may-improve-renal-and-mortality-outcomes/

Leave a Reply